StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood
StemCyte is a portfolio company of Microbio Group focusing on new drug discovery in cell therapy with operations in the U.S., Taiwan, and India
BALDWIN PARK, Calif., Jan. 26, 2022 — Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company’s clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB). [Read more…]